Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

A Pilot Study of Exercise in Patients With Docetaxel-Based Chemotherapy for Hormone Refractory Prostate Cancer

This study has been completed.
Cross Cancer Institute
Information provided by (Responsible Party):
AHS Cancer Control Alberta Identifier:
First received: December 30, 2005
Last updated: February 24, 2016
Last verified: March 2012
This study aims to provide preliminary data on the feasibility and outcomes of a 12 week exercise program on the quality of life of men with hormone refractory prostate cancer receiving docetaxel-based chemotherapy.

Condition Intervention Phase
Prostatic Neoplasms
Neoplasm Metastasis
Palliative Care
Behavioral: Exercise training
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Pilot Study of Exercise in Patients With Docetaxel-Based Chemotherapy for Hormone Refractory Prostate Cancer

Resource links provided by NLM:

Further study details as provided by AHS Cancer Control Alberta:

Primary Outcome Measures:
  • feasibility (recruitment, adherence, safety)

Secondary Outcome Measures:
  • quality of life
  • functional abilities

Estimated Enrollment: 30
Study Start Date: February 2006
Study Completion Date: November 2007
Primary Completion Date: November 2007 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • diagnosis of prostate cancer
  • receiving docetaxel-based chemotherapy at the CCI
  • age 18 years or over
  • approval of oncologist
  • informed written consent

Exclusion Criteria:

  • life expectancy less than 6 months
  • Karnofsky performance score less than 70
  • contraindications for exercise (e.g. uncontrolled cardiac, respiratory, hypertensive or psychiatric disorder)
  • unable to understand, read, write and speak English
  • unable or unwilling to attend supervised exercise sessions 3 times weekly
  • unable or unwilling to complete outcome assessments
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00271687

Canada, Alberta
Cross Cancer Institute
Edmonton, Alberta, Canada, T6G 1Z2
Sponsors and Collaborators
AHS Cancer Control Alberta
Cross Cancer Institute
Principal Investigator: Kerry Courneya, M.D. Cross Cancer Institute
  More Information

Responsible Party: AHS Cancer Control Alberta Identifier: NCT00271687     History of Changes
Other Study ID Numbers: SP-14-0049 / 22262
Study First Received: December 30, 2005
Last Updated: February 24, 2016

Keywords provided by AHS Cancer Control Alberta:
exercise therapy
activities of daily living
quality of life

Additional relevant MeSH terms:
Prostatic Neoplasms
Neoplasm Metastasis
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Genital Diseases, Male
Prostatic Diseases
Neoplastic Processes
Pathologic Processes
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action processed this record on May 25, 2017